Cancer Manag ResBayoumi Y, Heikal T, Darweish H. Survival benefit of adjuvant radiotherapy in stage III and IV bladder cancer: results of 170 patients. Cancer Manag Res 2014;6:459-65.Bayoumi , Heikal T, Darweish H, et al. Survival benefit of adjuvant radiotherap...
The present study analyzed the survival rate in patients with stage T2-T3a bladder cancer who had been treated by radical cystectomy. The records of 50 patients with T2-T3a NO tumor, submitted to pelvic lymphadenectomy and radical cystoprostatectomy, were reviewed to determine the prognosis in ...
The Phase 3 trial will continue to evaluate a dual primary endpoint of overall survival. “Up to half of patients with bladder cancer who undergo surgery will experience recurrence within a year, underscoring the need for new treatment options in the adjuvant setting,...
Stage D squamous cancer of the bladder: report of a seven-year survival after cystectomy. Stage D squamous cancer of the bladder: report of a seven-year survival after cystectomy.Mackenzie AR, Scheinman HZ.A R MackenzieH Z ScheinmanMt Sinai J MedMount Sinai Journal of Medicine New York......
(39%) patients in the docetaxel group had treatment-related grade 3-4 adverse events, and one (<1%) patient in the atezolizumab group versus three (2%) patients in the docetaxel group died from a treatment-related adverse event.Atezolizumab significantly improved survival compared with docetaxel ...
Both univariate and multivariate analyses showed that patients from affluent areas had better survival than patients from deprived areas for cancers of the lung, breast, colorectum, bladder, prostate, uterus and cervix. Stage of disease at diagnosis did not explain the survival differences by ...
et al. Disease-free survival for 9 years after liver resection for stage IV gallbladder cancer: Report of a case. Surg Today 25, 750–753 (1995). https://doi.org/10.1007/BF00311494 Download citation Received26 July 1994 Accepted03 March 1995 Issue DateAugust 1995 DOIhttps://doi.org/...
TUMOR PROGRESSION AND SURVIVAL OF PATIENTS WITH HIGH GRADE, NONINVASIVE PAPILLARY (TaG3) BLADDER TUMORS: 15-YEAR OUTCOME Tumor progression and survival of patients with high grade Ta bladder tumors followed for 15 to 20 years were evaluated. A total of 148 patients with Ta an......
Merck’s anti-PD-1 therapy, met its overall survival (OS) endpoint, in combination with chemotherapy as pre-operative (neoadjuvant) treatment and then continuing as a single agent after surgery (adjuvant) for the treatment of patients ...
First introduced in AJCC 8th edition (Amin: AJCC Cancer Staging Manual, 8th Edition, 2017) AJCC/TNM staging is used for predicting outcomes of thymic tumors, such as recurrence (in the lower stages) and disease specific survival (in the higher stages); reference numbers are available (J Thora...